Myocardial Infarction News and Research

RSS

Twice-yearly blood pressure treatment could reshape hypertension care, but doctors warn against a “fire-and-forget” approach

Long-acting RNA interference therapy for hypertension could shift blood pressure control from daily pill-taking to scheduled, system-led protection. But the authors warn that this “vaccine-like” model must preserve lifestyle support, monitoring, and follow-up to avoid clinical disengagement.

27 Apr 2026

Trends reveal growing burden of deaths from non-ischemic cardiogenic shock

New data from the CDC WONDER database finds deaths from heart attack-related cardiogenic shock (CS) decreased between 1999 and 2020, but deaths linked to heart failure (HF) and abnormal heart rhythms have risen sharply since 2010, particularly among men.

24 Apr 2026

Elevated Lp(a) levels associated with residual cardiovascular risk

New data analyzing more than 20,000 patients from three major NIH studies show that elevated Lipoprotein(a) [Lp(a)] is associated with residual cardiovascular risk and warrants aggressive risk reduction.

24 Apr 2026

M-TEER procedure effectively treats mitral regurgitation in patients with calcification

Results from a new analysis show that patients with mitral annular calcification (MAC) who undergo minimally invasive mitral transcatheter edge-to-edge repair (M-TEER) experience similar reductions in mitral regurgitation (MR) and improvement in quality of life compared to those seen in patients without calcification.

24 Apr 2026

COVID-19 patients with STEMI show higher one-year mortality rates

Findings from the North American COVID-19 Myocardial Infarction (NACMI) registry demonstrate significantly higher one-year mortality rates in patients with COVID-19 and ST-elevation myocardial infarction (STEMI) compared to patients with STEMI alone.

24 Apr 2026

Preliminary model developed to improve cardiovascular risk prediction in Latin America and the Caribbean

A preliminary model to improve the prediction of cardiovascular risk in Latin America and the Caribbean was presented today at ESC Preventive Cardiology 2026, the annual congress of the European Association of Preventive Cardiology (EAPC), a branch of the European Society of Cardiology (ESC).

24 Apr 2026

Heatwaves and coldwaves linked to increase in major cardiovascular events

Heatwaves and coldwaves are associated with increases in major cardiovascular events that are exacerbated by air pollution.

24 Apr 2026

Study identifies key risk factors driving MASLD across populations

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects approximately 32% of the US adult population.

23 Apr 2026

Drug-coated balloons reduce the need for permanent heart stents

A new sub-study suggests that using a sirolimus-eluting balloon (SEB), a drug-coated balloon, can reduce the number of stents a patient may need, making it a safe and effective way to treat certain heart attacks or unstable chest pain.

23 Apr 2026

Early heart pump use improves survival in patients experiencing cardiogenic shock

Findings from the Can Escalation Reduce Acute Myocardial Infarction Mortality in Cardiogenic Shock (CERAMICS) registry demonstrate that early use of a small heart pump improves outcomes in patients experiencing a severe form of heart failure called cardiogenic shock after suffering from a heart attack and undergoing a stenting procedure.

23 Apr 2026

Treatment goals guide cardiogenic shock care more often in women

New findings from the Northwell-Shock Registry show that while women with acute myocardial infarction-related cardiogenic shock (AMI-CS) are less likely to receive invasive treatments, clinical decisions are driven by objective markers of illness severity rather than sex.

23 Apr 2026

Tirzepatide significantly reduces cardiovascular risk in high-risk patients

Two new studies show that tirzepatide, a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist (RA), significantly reduces cardiovascular risk in high-risk patients, including those undergoing percutaneous coronary intervention (PCI) and those with obesity undergoing transcatheter aortic valve replacement (TAVR).

23 Apr 2026

Cognitive decline may signal heart trouble years before a cardiovascular event

In a large ASPREE and ASPREE-XT nested case-control study of older adults without prior cardiovascular disease, people who later experienced a CVD event showed faster cognitive decline beginning roughly 3 to 8 years before the event. Processing speed declined earliest, suggesting that subtle cognitive changes may emerge well before overt cardiovascular disease.

21 Apr 2026

Early genetic signals connect diabetes subgroups to heart disease risk

A growing body of research shows that diabetes can be stratified into five different subgroups. Researchers at Lund University have now investigated whether a person's genetic predisposition to different diabetes subgroups can help assess the risk of developing coronary artery disease.

7 Apr 2026

How gut microbes may shape heart attack damage and recovery

This review argues that gut microbes and the metabolites they produce, especially SCFAs and TMAO, may shape how the heart responds to myocardial infarction through epigenetic pathways such as DNA methylation, histone modification, and non-coding RNAs. It also outlines potential intervention routes, including diet, probiotics, postbiotics, and metabolite-targeted therapies, while noting that much of the evidence remains translational and not yet clinically definitive.

6 Apr 2026

Flu vaccination may cut heart attack and stroke risk after infection

In Danish adults aged 40 years or older, laboratory-confirmed influenza was linked to a sharp short-term rise in first-time heart attack and stroke risk, especially in the first 7 days after infection. Prior same-season influenza vaccination was associated with about half the excess cardiovascular risk among infected individuals, suggesting possible protection even in breakthrough cases.

6 Apr 2026

Evolocumab trial could reshape how doctors treat high-risk cholesterol patients

A new ACC/AHA dyslipidemia guideline and editorial argue that guideline development is rigorous but can lag behind fast-moving science, using the VESALIUS-CV trial as a clear example. The trial showed that intensive LDL cholesterol lowering with evolocumab reduced cardiovascular events in high-risk patients without prior heart attack or stroke, with implications for future guideline updates.

6 Apr 2026

American Heart Association's 9 diet rules to lower heart disease risk

The AHA's dietary guidance emphasizes food choices over fad diets to reduce heart disease risk and improve cardiovascular health across all life stages.

2 Apr 2026

Wegovy® (semaglutide injection) 2.4 mg recommended by NICE to reduce risk of major adverse cardiovascular events, including heart attacks and strokes, in adults with established cardiovascular disease and overweight or obesity (BMI ≥ 27 kg/m2)

NICE has recommended Wegovy® (semaglutide injection) 2.4 mg as the first GLP-1 RA to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight (BMI ≥ 27 kg/m2).

From Novo Nordisk 2 Apr 2026

Dual imaging reveals hidden causes of heart attacks without blockages

When Ashley Perlow felt a sharp pain shoot across her chest and into both wrists, she didn't think it could be a heart attack. She was 36, a new mom, and otherwise healthy.

30 Mar 2026